The agency requested the labeling changes for the following medications: Ambien/Ambien CR, Butisol
Sodium, Carbrital, Dalmane, Doral, Halcion, Lunesta, Placidyl, Prosom, Restoril, Rozerem, Seconal and Sonata.
The label change affects drugs including Zolpidem, marketed as Ambien/Ambien CR by Sanofi-Aventis; butabarbital, marketed as Butisol
Sodium by Medpointe Pharmaceuticals HLC; flurazepam, marketed as Dalmane by Valeant Pharmaceuticals; quazepam, marketed as Doral by Questcor Pharmaceuticals; triazolam, marketed as Halcion by Pharmacia & Upjohn Inc.
In 1988, HQ finally threw caution to the winds and published a straight-forward Drug Dosage Table listing the lethal dosages of eighteen common prescription drugs: Amytal, Butisol
, Valium, Dalmane, Doriden, Noctec, Dilaudid, Miltown, Noludar, Demerol, Dolophine, Norflex, Seconal, Nembutal, Darvon, codeine, morphine, and phenobarbital.